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Abstract
Purpose of review—Injury to the small bowel from ionizing radiation occurs commonly in
patients undergoing cancer therapy and less commonly in instances of accidental radiation
overexposure. Several lines of evidence now suggest that dynamic interactions between the host’s
enteric microbiota and innate immune system are important in modulating the intestinal response
to radiation. Here, we will review recent developments in the area of acute radiation enteropathy
and examine the current state of knowledge regarding the impact of host–microbial interactions in
the process.
Recent findings—There is promise in the development and testing of new clinical biomarkers
including serum citrulline. Toll-like receptor agonists and innate immune system signaling
pathways including nuclear factor-kappa B profoundly alter intestinal epithelial cell apoptosis and
crypt survival after radiation exposure. Germ-free conditions, probiotics and antibiotics are each
identified as modifiers of disease development and course. A human study suggested that luminal
microbiota composition may influence the host’s intestinal response to radiation and may change
in those developing postradiation diarrhea.
Summary—New knowledge implies that investigations aimed at deciphering the microbiome–
host interactions before and after small bowl radiation injury may eventually allow prediction of
disease course and offer opportunities for the development of novel therapeutic or prophylactic
strategies.
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Introduction
The mammalian microbiome, as it relates to health and disease, has received increasing
attention in medical research over the last decade. The human body is inhabited by at least
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10 times more bacteria than the number of somatic and germline cells. The National
Institutes of Health has funded the Human Microbiome Project (HMP) as a roadmap
initiative to characterize the human microbiome in five body sites from healthy volunteers,
including the gastrointestinal tract [1•]. Perhaps not coincidentally, an enhanced interest in
probiotic bacteria (those which confer health benefits) has developed recently among both
the scientific community and lay public. The majority of studies addressing pathogenic or
beneficial microbial influences on gastrointestinal illnesses have focused on irritable bowel
and the inflammatory bowel diseases. More recently, several lines of evidence have emerged
that link the presence and composition of the luminal microbiota to the intestinal response to
radiation. These include relative radiation resistance of germ-free mice, altered intestinal
responses to radiation associated with colonization by commensal and probiotic bacterial
species and recognition that stimulation of, or alteration in, innate immune system pathways
modifies host responses to radiation. Radiation enteropathy remains a common complication
for patients receiving abdominal or pelvic radiotherapy for cancer. Prophylactic or
therapeutic strategies against radiation enteropathy are currently limited. However, as in
other intestinal disorders, recent studies aimed at elucidating functions of the host–
microbiome relationship in radiation injury have provided insight into both disease
pathophysiology and potential therapeutics. Our opinion will provide a background review
on radiation-induced intestinal injury while examining in greater detail the data for
microbial influences on this disease entity.
Radiation enteropathy in clinical medicine
Radiation therapy is used commonly for many forms of solid cancers including those that
develop within the abdominal or pelvic cavities. A particular challenge that remains for the
clinician is the lack of an available quantitative biomarker to measure the presence and
degree of intestinal damage.
Scope and impact
More than 50% of patients with cancer receive radiation as a component of their treatment.
The small intestine is rarely a primary target in radiotherapy, but by nature of its size and
extent, it often receives exposure resulting in collateral damage. The rapidly proliferating
mucosal lining of the small intestine is highly radiosensitive, and the resulting cell death
leads to symptoms of malabsorption, including bloating, diarrhea and dehydration.
Abdominal pain, anorexia, nausea and vomiting can also occur and are amplified by
concurrent chemotherapy [2,3]. Symptoms adversely affect patient quality of life and can be
severe enough to require hospitalization. The damaging effects related to small intestinal
injury are a major reason for dose limitation and can force discontinuation of radiotherapy,
impacting overall chances for cure of malignancy.
Patients typically experience symptoms from acute small intestinal injury after the first or
second week of radiotherapy [4]. The effect is dosage-dependent wherein low doses lead to
mild and reversible disease and higher doses result in more severe and potentially
irreversible damage. Thus, clinical regimens are usually designed to offer fractionated low-
dosage (<2 Gy) therapy in multiple sessions over the course of weeks. Extensive planning
goes into treatment field design for radiation therapy to minimize the amount of small bowel
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which is exposed. Regardless, it is estimated that up to 70% or more of patients experience
adverse gastrointestinal side effects by 3 weeks into therapy. Most of these acute symptoms
subside by 2–6 weeks following completion of radiation therapy. Chronic severe
complications of radiation enteropathy include dysmotility, strictures and fistulas, and occur
in approximately 6% of patients 1 to 2 years after radiation therapy [5]. Interestingly, both
acute and chronic radiation therapy-related toxicities may be more severe in patients with
preexisting conditions of intestinal compromise or microbial dysbiosis such as those
occurring in patients with inflammatory bowel diseases [6,7].
Diagnosis
The diagnosis of acute radiation enteropathy is usually presumptively based on symptom
type and time of onset. Basic laboratories, stool studies and abdominal imaging can be
performed depending on symptom severity, but are often uninformative. Endoscopic
biopsies are rarely used, although they may reveal histologic changes consistent with
radiation damage. No specific biomarkers for radiation enteropathy are in common use;
however, new potential serum or stool markers are being tested. Citrulline is a nitrogen-
containing end product of small bowel enterocyte metabolism. Serum citrulline has been
evaluated as a biomarker for functional enterocyte mass [8]. In radiation enteropathy, testing
of the feasibility and functionality of this biomarker in mice and in humans has revealed that
it shows promise as a novel diagnostic test [9–11]. Fecal calprotectin is another potential
biomarker, which has been shown to significantly increase after pelvic radiation [11].
However, as a neutrophil-derived protein, calprotectin is not small bowel-specific.
Eosinophilic cationic protein levels [12] and C-reactive protein levels [13] have also been
found to be increased in patients following pelvic irradiation, although not consistently [11].
It is possible that in the future, sequential evaluation of a cluster of markers will prove most
informative for diagnosis and monitoring.
Pathophysiology of small bowel radiation injury
Acute radiation injury to the small intestine has been well documented in animal models.
When interpreting the literature, it is useful to recognize that whereas clinical medicine uses
small fractionated doses of ionizing radiation, most animal studies evaluating mechanisms
of disease use higher dose, single-exposure regimens, as would be encountered in accidental
or warfare-associated ionizing radiation overexposure. Figure 1 ([14–18,19•, 20–24,25• ,26•,
27]) summarizes several recent findings.
Epithelial and endothelial responses
Radiation-induced small intestinal injury is characterized by cell loss in the progenitor cell
compartment [28] and a dose-dependent loss of barrier properties [29–31]. Ionizing
radiation causes a wide diversity of functional disorders in the small intestine, including
altered motility [32,33], disrupted absorption of carbohydrates [34], amino acids and bile
acids [35], and a more thrombophilic endothelium due to the induction of inflammatory cell
adhesion to the endothelium [36] and increased expression of endothelial von Willebrand
factor [37].
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It has traditionally been assumed that the radiation gastrointestinal syndrome that ensues
with exposure to high doses of radiation or cumulative lower doses results from the direct
killing of the rapidly proliferating epithelial stem cells, depletion of the differentiated
parenchymal cells and subsequent loss of tissue function [38]. However, vascular damage
also ensues when the small intestine is exposed to ionizing radiation [39]. A study [14]
published in 2001 suggested that the radiation gastrointestinal syndrome is a direct
consequence of an early (4-h) wave of apoptosis in the intestinal vascular endothelial cells.
Recently, this assertion was challenged by Schuller et al. [15] who exposed two groups of
mice to an equivalent dose of total body irradiation (TBI), then directly targeted intestinal
endothelial cells in one of the groups of mice with up to 27-Gy neutron beam irradiation and
found no additional intestinal crypt stem cell loss or murine death related to the
gastrointestinal syndrome.
Unanticipated overexposure to ionizing radiation
In clinical medicine, small fractionated doses of radiation are used. In mice exposure to
doses of 8 Gy or higher leads to sterilization of individual small intestinal crypts, a process
in which all of the actual and potential stem cells are inactivated. The survival of one or
more clonogenic cells in a given crypt allows the regeneration of that crypt. Doses of 15 Gy
and higher sterilize virtually all of the crypt stem cells, resulting in complete loss of the
intestinal villi and death from the radiation gastrointestinal syndrome in 4–5 days [15]. This
syndrome is characterized by breaches in the intestinal mucosa, translocation of commensal
intestinal bacteria and sepsis, and it is relevant in cases of bioterrorist attacks, nuclear
accidents, medical errors and in appropriately fractionated dosing of therapeutic radiation to
people whose tissues are exquisitely radiosensitive.
Linking the microbiota to the intestinal response to radiation
It had previously been observed that germ-free mice have improved survival as compared
with colonized mice when exposed to equivalent doses of radiation [40]. However, the
impact of the intestinal microbiota on the pathogenesis of the radiation gastrointestinal
syndrome was not understood until a more recent work by Crawford and Gordon [16]. Here,
hematopoietic rescue by bone marrow transplantation after lethal ionizing radiation was
used to demonstrate that conventionally raised mice still exhibited earlier death than germ-
free mice [16]. Using Rag1 knockout mice, they also showed that mature lymphocytes are
not required for the development of lethal radiation enteropathy. Mechanistically, the
investigation also suggested that increased expression of a fibrinogen/angiopoietin-like
protein, fasting-induced adipose factor, which is normally suppressed by luminal microbiota,
confers endothelial and lymphocyte radioresistance.
Recognition of commensal intestinal bacteria or their products by Toll-like receptors (TLRs)
is necessary for the regulation of intestinal homeostasis [41]. It is largely through binding to
these receptors and the subsequent activation of the nuclear factor-kappa B (NF-κB) family
of transcription factors that commensal bacteria have been shown to influence the small
intestinal epithelial response to various forms of injury. Recent animal models have revealed
that this is true for radiation-induced injury. Egan et al. [17] showed increased intestinal
epithelial cell (IEC) apoptosis in mice with selected ablation of NF-κB signaling through
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IκB kinase, a common activation pathway for TLR signaling. This finding corresponded
with increased expression and activation of the tumor suppressor p53. Mice in which the
NF-kB p50 gene has been disrupted were shown to be more sensitive to TBI-induced
lethality than are wild-type mice [18]. These findings demonstrate the physiological
importance of NF-κB activation in protection against radiation-induced death in the
epithelium in vivo, and directly link intestinal commensal bacteria to the regulation of
radiation-induced IEC apoptosis. Recent mouse knockout studies have revealed that
bacterial products also activate signaling pathways other than the NF-κB pathway to protect
IECs from radiation-induced apoptosis [19•].
Both endogenous and exogenous sources of prostaglandins have been shown to confer
protection to intestinal crypts that are exposed to radiation. In mice, parenterally
administered lipopolysaccharide, a TLR4 ligand, increased endogenous intestinal
prostaglandin production, thereby improving intestinal crypt survival after irradiation [20].
Exogenous administration of a prostaglandin E2 (PGE2) analogue prior to radiation also
increases the number of surviving intestinal crypts. Several studies have demonstrated that
the radioprotective effect of prostaglandins on the gut is a cyclooxygenase (COX)-1-
dependent, COX-2-independent event. Irradiated COX-1−/− mice have increased crypt
epithelial apoptosis, decreased clonogenic stem cell survival and diminished PGE2 synthesis
as compared with wild-type littermates [21]. Administration of indomethacin, which inhibits
both COX-1 and COX-2, to a mouse prior to radiation increases radiation-induced IEC
apoptosis and decreases intestinal crypt survival [22]. However, selective COX-2 inhibitors
have no effect on crypt survival; likewise COX-2−/− mice have a similar response to
radiation to wild-type mice. So, the COX-1-dependent production of endogenous PGE2
appears to be an important downstream mediator of TLR signaling by which bacterial
products promote IEC survival and proliferation in the response to radiation [23]. The
biologic effects of PGE2 have been shown to be mediated via AKT activation by the plasma
membrane G-protein-coupled receptor EP2 [24], thereby preventing Bax translocation to the
mitochondria [42].
Human polymorphisms and variations in microbiome
There are emerging, although not yet matured, data supporting the role of host and microbial
genetic influences on the radiosensitivity of the small intestine. A recent study [43]
identified a correlation between single-nucleotide polymorphisms in mice and the amount of
jejunal crypt cell apoptosis after 2.5-Gy TBI. Gene expression microarrays have also been
used in attempts to predict the radiosensitivity of normal tissue [44].
An intriguing recent study [45•] involving a small number of patients used DNA
fingerprinting with 16S ribosomal RNA denaturing gradient gel electrophoresis (DGGE) to
show different fecal microbial profiles in people receiving radiation who experienced
diarrhea from those who received radiation and maintained normal stool consistency. They
evaluated stool before, during and after radiation, and proposed that a dysbiosis was linked
to changes in bowel habits rather than the radiation exposure itself. Interestingly, the
microbial profiles of individuals before receiving radiation clustered in three similarity sets
that matched closely the control, the ‘no diarrhea’ and the ‘diarrhea’ groups, suggesting that
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the initial intestinal microbial composition of each individual could be a determinant for
developing postirradiation diarrhea.
Current management principles
In cancer therapy, use of well planned [46,47], fractionated dose regimens with specific
patient positioning remains key to minimizing symptoms of radiation enteropathy.
Additionally, numerous pharmacologic therapies have been tested for reducing symptoms.
Antispasmodic and antidiarrheal agents are effective for some patients. Cholestyramine has
been shown to be effective in reducing bile salt-associated diarrhea, which can occur with
radiation enteropathy [48]. Amifostine, a broad-spectrum, free-radical scavenging
cytoprotectant, is used as an adjuvant with treatment of some malignancies [49]. Although
the benefits of this drug are clear for xerostomia, its ability to prevent radiation enteropathy
has not been proven and the side effect of hypotension has tempered interest in routine use.
Most current therapies for radiation enteropathy are initiated only after symptoms develop.
As the percentage of patients who develop small bowel symptoms is high, widespread use of
an effective prophylactic agent would likely be adopted if it became available. An ideal
prophylactic radioprotectant for the small intestine would need to fulfill specific
requirements including the possession of an ability to preserve or enhance the antitumor
efficacy of radiation; the provision of wide-ranged normal tissue protection with a low-
toxicity profile and the allowance of easy, safe and cost-effective administration.
Microbial manipulation in therapy or prevention
Development of small intestinal radioprotectants has primarily focused on antioxidants [50–
54], modifiers of inflammation [55–57], growth factors [58–60] and regulators of IEC
apoptosis [61,62]. Yet, recent evidence suggests that manipulation of the intestinal luminal
microbiota or the administration of medications adapted from commensal or probiotic
bacteria holds promise in providing prophylactic and possibly postexposure enteric
radioprotection.
Bacterial product-based therapies
Burdelya et al. [25••,63] recently evaluated a polypeptide drug derived from Salmonella
flagellin that binds to TLR5 and activates NF-κB signaling. A single injection of this agent
improved survival in mice exposed to radiation by limiting apoptosis and preserving cell
proliferation in the epithelial crypts and lamina propria of the small intestine. However,
protection was conferred only when mice were exposed to doses below those that
universally cause the radiation gastrointestinal syndrome, and only if the agent was
administered 15–60 min before exposure. In similar experiments using rhesus macaques, the
investigators observed that the TLR5 agonist increased survival and had protective effects
on bone marrow, although they did not provide data on the effect of the agonist on the
gastrointestinal tract of the monkeys. Remarkably, this drug did not appear to decrease
tumor radiosensitivity in the mouse model used. Hence, this TLR5 agonist is potentially
useful as a prophylactic before therapeutic radiation, but may not be adequate as a treatment
for the radiation gastrointestinal syndrome, as in the case of a nuclear accident or attack.
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Probiotics are live microbial organisms, most often bacteria, which confer beneficial effects
to the host when consumed. With increasing evidence suggesting that imbalance of the
intestinal microbiota may play a significant role in the pathogenesis of radiation enteropathy,
probiotic bacteria are now attracting interest as potential radioprotectants. Single and
multistrain probiotic preparations have been evaluated in both animal models and humans
over the last few decades. In rodents, Lactobacillus species have been shown to reduce
radiation-induced small intestinal damage, Gram-negative bacteremia, endotoxemia and
death [26•,64,65]. Primary endpoints were not achieved for probiotics in small trials in
which humans underwent pelvic radiation for cancer; however, individuals receiving
Lactobacillus supplementation showed a trend toward having less severe symptoms
[27,66,67]. In the largest human trial [68] to date, patients taking the probiotic mixture
VSL#3 experienced radiation-induced diarrhea less frequently than patients taking a placebo
in a double-blind study involving almost 500 patients. Timing of probiotic administration,
prophylactic versus therapeutic, respectively, may explain the more robust results identified
in animal studies as compared with human trials. Early reports also suggest that soluble
secreted factors from probiotic bacteria may be responsible for physiologic benefits
observed in radiation [26•] as in other injury models [69]. As probiotic bacteria are
inexpensive and would be predicted to offer extensive tissue protection with low toxicity,
further investigation into their role as intestinal radioprotectants is warranted.
Antibiotics
Antibiotics have been considered for decades as a potential treatment option for radiation
enteropathy [70]. Researchers at the Armed Forces Radiobiology Research Institute used
antibiotics in several radiation mouse models [71–73]. Limitations to these studies included
their focus on the activity of various antibiotics specifically against orally ingested
pathogens, their use of bacterial translocation to the liver and mortality as primary readouts,
and their evaluation of radiation doses that were not sufficient to cause the radiation
gastrointestinal syndrome. In their most recent review, this group summarized their findings
and concluded that the potential use of several different antimicrobial agents from various
classes may be effective for treating infection after exposure to radiation, but they do not
identify a superior agent [74].
Intestinal commensal bacteria translocate across the intestinal mucosa and cause sepsis and
early death in response to high doses of radiation. Yet, the aforementioned studies linking
TLR binding by bacterial products to protection of the intestinal epithelium and the host
against radiation-induced damage suggest that some commensal intestinal bacterial species
provide protective functions in the response to radiation. Hence, an antibiotic that uniquely
targets bacterial organisms that tend to translocate after exposure to radiation, while sparing
bacterial species that are shown to be protective in the response of the intestinal epithelium
and the host to radiation, may be optimal. This concept also lends support to the
prophylactic and/or therapeutic potential of administrating both an antibiotic and a probiotic
to people exposed to radiation.
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Radiation injury to the small bowel remains an important clinical problem for which few
therapeutic strategies exist. Several lines of evidence, which were reviewed here, suggest
that dynamic interactions between the host’s enteric microbiota and innate immune system
modulate the intestinal response to radiation. Probiotics, antibiotics and bacterial-derived
peptides and byproducts can modify radiation-induced injury and symptom severity. How to
best harness the influence of these microbial symbionts remains to be determined. Future
laboratory studies should be aimed at identifying specific prebiotic, probiotic, antibiotic or
all regimens that optimize normal tissue radioresistance and tumoral radiosensitization.
Bacterial-based compounds or secreted products will likely be an area of fruitful
investigation. Clinical studies in this area should initially focus on clarifying how intestinal
microbial compositions shift in response to radiation. Using this knowledge, strain-specific
probiotics could be administered to increase bacterial species that best confer host
radioprotection. Likewise, antibiotic regimens could be developed that selectively target
bacterial species that are found to proliferate, translocate and cause sepsis following
exposure to radiation, while possessing minimal activity against the protective bacterial
populations. Subsequent clinical studies should be aimed at determining the safety, efficacy
and applicability of the developing therapeutic agents and regimens. Recent years have seen
an explosive growth in knowledge associating the microbiome to human health; the
prevention or treatment of small intestinal radiation injury should serve as a particularly
productive target for future investigations in this area.
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Figure 1. Modifiers of acute small intestinal radiation injury
The small intestinal response to radiation is altered by signaling induced by luminal bacteria
or bacterial-based products. Experimental models and human trials suggest Lactobacillus
species or their soluble secreted proteins alone may protect intestinal crypts against damage
from radiation exposure [26•,27]. Flagellin, a TLR5 ligand that activates the NF-κB
pathway, protected IECs from radiation-induced apoptosis and increased host survival when
injected into mice before lethal doses of radiation [25••]. LPS, a TLR4 ligand that is found
in the outer membrane of Gram-negative bacteria, increased both endogenous intestinal
prostaglandin production and intestinal crypt survival in mice exposed to 14-Gy radiation
when injected parenterally 2–24 h prior to exposure [20]. Endogenous PGE2 has been shown
to decrease murine IEC apoptosis and increase IEC proliferation in response to radiation
[23]. Conversely, blocking pathways that are activated by bacterial products have been
shown to have detrimental effects on the ability of IECs and crypts to survive radiation
insults. The E. coli STa is a ligand for GC-C, an IEC transmembrane receptor. UGN is a
peptide hormone that binds to and activates GC-C. Mice in which GC-C or UGN is knocked
out have increased jejunal IEC apoptosis 3 h after 5-Gy radiation as compared with wild-
type counterparts [19•]. Indomethacin blocks PGE2 production by inhibiting COX-1 and
COX-2, thereby increasing IEC apoptosis and intestinal crypt ablation [22]. Similarly,
irradiated COX-1−/− mice have diminished PGE2 synthesis, leading to increased crypt
epithelial apoptosis and decreased clonogenic stem cell survival [21]. Irradiated EP2
receptor−/− mice also have decreased intestinal crypt survival and a 1.6-fold increase in IEC
apoptosis [24]. Blocking NF-κB activation by deleting the p50 subunit of the NF-κB
complex [18] or the canonical NF-κB activation kinase [17] results in increased radiation-
induced IEC apoptosis in mice. Although debate still exists as to the degree of importance of
endothelial apoptosis in acute intestinal outcomes after high-dose radiation exposure
[14,15], endothelial apoptosis is shown to be lower in germ-free than conventionally raised
mice [16]. COX, cyclooxygenase; E. coli STa, heat-stable enterotoxin of Escherichia coli;
GC-C, guanylate cyclase C; IEC, intestinal epithelial cell; KO, knocked out; LPS,
lipopolysaccharide; NF-κB, nuclear factor-kappa B; PGE2, prostaglandin E2; TLR, Toll-like
receptor; UGN, uroguanylin.  Limits acute intestinal injury from radiation,  contributes
to acute intestinal injury from radiation.
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